导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.96% | 1966/4750 |
| 近一周 | -2.47% | 2265/5436 |
| 近一月 | -4.08% | 2190/5395 |
| 近一季 | -7.64% | 2461/5185 |
| 近半年 | -6.52% | 3087/4896 |
| 近一年 | 6.03% | 1509/4344 |
| 近两年 | 69.65% | 974/2945 |
| 近三年 | 38.46% | 756/2246 |
| 成立以来 | 62.03% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.33% 1572/4961 |
16.11% 1599/5312 |
- - |
- - |
| 2025 | 33.71% 1099/4813 |
3.20% 1155/3635 |
4.86% 694/4076 |
19.94% 2071/4524 |
3.01% 783/4813 |
| 2024 | 8.17% 1583/3463 |
-0.47% 1115/2808 |
-3.76% 1416/3014 |
13.37% 2182/3129 |
-0.39% 1402/3463 |
| 2023 | -5.43% 739/2656 |
8.26% 475/2280 |
-3.72% 877/2385 |
-4.11% 1065/2515 |
-5.38% 1338/2655 |
| 2022 | -14.85% 397/2207 |
-9.35% 322/1919 |
4.35% 1020/2016 |
-8.56% 209/2113 |
-1.55% 1711/2208 |
| 2021 | 4.80% 563/1822 |
-3.20% 776/1255 |
10.30% 479/1330 |
-2.29% 562/1466 |
0.45% 1108/1822 |
| 2020 | 29.59% 534/1250 |
-3.29% 296/1028 |
19.12% 311/1067 |
7.99% 746/1164 |
4.17% 860/1184 |
| 2019 | 24.74% 612/1092 |
26.26% 420/739 |
-9.68% 682/788 |
2.09% 326/850 |
7.14% 480/918 |
| 2018 | - - |
- - |
- - |
-6.18% 393/660 |
-11.83% 361/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 华宝中证500增强A VS. 长安沪深300非周期A(740101) |